spacer
home > ict > autumn 2008 > asian agility
PUBLICATIONS
International Clinical Trials

Asian Agility

China, constituting a quarter of the world’s population and with an exploding pharmaceutical industry, is on track to soon become one of the world’s top five markets for pharmaceutical products. It is also becoming one of the world’s major settings for drug research and development, including clinical trials.

Indeed, recent reports indicate that China has surpassed India in the number of registered clinical trials currently underway – an important measure of drug research activity. Conducting trials in China carries the benefit of reducing the time for a drug to reach its burgeoning local market, and also presents a large available patient pool at a time when global patient recruitment is becoming increasingly difficult.

As international clinical trials in China gain in frequency and importance, procuring the right comparator drugs – often an essential element in clinical pharmaceutical trials – becomes increasingly critical. So, successfully using comparator products in China requires a thorough understanding of that country’s labyrinth of administrative procedures relating to clinical trials and drug regulation.

THE INDUSTRY IN CHINA

China’s pharmaceutical industry has been in a state of continuous change over much of its contemporary history, driven by the stream of regulations issued by the Chinese State Food and Drug Administration (SFDA) and its predecessors affecting...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Angus G Cameron is a Director and Senior Vice President of Pharmarama, the US affiliate of BR Pharma Ltd. He also serves as Head of Business Development at BR Pharma Limited, where his focus is on growth strategies for the firm. He has been a featured speaker at industry conferences worldwide. Prior to his tenure at Pharmarama and BR Pharma, Angus was Senior Partner of Aeomica Ltd, a life sciences business consultancy which he co-founded in 2002. Prior to Aeomica, he served as Senior Vice President (Europe) of Intergen Company, a New York-based high-tech producer of pharmaceutical and academic research components. Angus also held senior management positions at Healthcare Technologies Ltd, Celltech Limited and Becton Dickinson Immunodiagnostics. He was a former Board member of the UK BioIndustry Association.
spacer
Angus G Cameron
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Europital forecast 30% CAGR from UK biotech for three years

Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement